<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02886026</url>
  </required_header>
  <id_info>
    <org_study_id>URU06</org_study_id>
    <nct_id>NCT02886026</nct_id>
  </id_info>
  <brief_title>Outpatient PDD Guided Laser Mediated Destruction of Bladder Tumors</brief_title>
  <acronym>LaserIII</acronym>
  <official_title>Is Outpatient PDD Guided Laser Mediated Destruction of Bladder Tumors (LMD-BT) as Good as Conventional Inpatient PDD Guided Transurethral Tumor Resection in Patients With Low Grade Non-invasive (Ta) Bladder Tumors?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Bispebjerg and Frederiksberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Bispebjerg and Frederiksberg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compare the efficacy of conventional photodynamic (PDD) guided transurethral
      bladder tumor resection in the operating theatre with outpatient PDD guided laser destruction
      of bladder tumors through flexible cystoscopes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective randomized two-part clinical trial comprising patients with recurrent pTa low
      grade bladder tumors.

      Study objectives and purpose:

        -  1st Objective: To evaluate whether small pTa bladder tumours can be removed with diode
           laser in an outpatient department with similar efficacy as by TUR-BT resection in the
           operating theatre.

        -  2nd Objective: To evaluate the patients experience of symptoms during laser treatment in
           the outpatient department (OPD) using quality of life (QOL) questionnaires (symptom
           evaluation) and Visual Analog Scale Score (pain evaluation).

        -  3rd Objective: To evaluate whether patients prefer standard transurethral bladder tumor
           resection (TUR-BT) in the operating theatre (OT) or laser treatment in the OPD.

        -  4th Objective: To evaluate the safety after laser treatment in the OPD.

      Efficacy:

        -  1st Endpoint: Proportion of patients with no tumor tissue in the bladder after 4 months
           and 12 months.

        -  2nd Endpoint: Visual Analog Scale Score (pain evaluation) in patients having tumor
           removed by laser in the OPD.

      General urinary problems and QOL one week after the laser treatment. The Danish validated
      questionnaire (QLQ- BLS24) from EORTC will be used.

        -  3rd Endpoint: Patients preference for either OPD laser treatment procedure or TUR-BT in
           the OT as inpatient procedure.

        -  4th Endpoint: Character and severity of adverse events in relation to the outpatient
           treatment.

      Study

      Inclusion criteria:

        1. Ta low grade bladder tumor recurrences

        2. Up to a tumor size of 1,5 cm

        3. Up to 6 tumors

        4. Eligible patients for TUR-BT

      Exclusion criteria:

        1. Patients with porphyria

        2. Known hypersensitivity to Hexvix® or porfhyrins

        3. Use of concomitant anticoagulants as Marevan, Marcoumar, and Pradaxa

        4. Dementia

        5. Macroscopic hematuria

        6. Pregnant or breast feeding women

        7. Expected poor compliance estimated by the investigators

        8. Patients &lt; 18 years

        9. Patients who do not read or understand Danish
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor recurrence histological identified in biopsy obtained during cystoscopy</measure>
    <time_frame>4 months</time_frame>
    <description>Numbers (%) of patients vith histological proven recurrence of bladder tumor after 4 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lower urinary symptoms caused by laser treatment.</measure>
    <time_frame>2 weeks</time_frame>
    <description>Using the EORTC questionnaire QLQ-BLS24 the extent of symptoms are given on a unique score from 0-100, with 0 being no symptoms and 100 are worst symptoms. Mean and range score in the two arms will be compared statistically.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects to laser treatment.</measure>
    <time_frame>2 weeks</time_frame>
    <description>Symptoms measured by one unique score according to the Clavien-Dindo grading system. Mean and range score in the two arms will be compared statistically.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain during laser treatment</measure>
    <time_frame>Evaluated immediately after laser treatment</time_frame>
    <description>The patients record pain on a visual analogue scale of 0-10. Zero corresponds to no pain. Ten correspond to the worst possible pain.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">248</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Inpatient TUR-BT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transurethral bladder tumor resection in operating theatre as inpatient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>laser bladder tumor destruction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Outpatient laser mediated destruction of bladder tumors (LMD-BT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bladder tumor resection using diathermia</intervention_name>
    <description>Conventional bladder tumor resection using diathermia</description>
    <arm_group_label>Inpatient TUR-BT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Diode laser (980 nm) tumor destruction</intervention_name>
    <description>Laser mediated destruction of bladder tumors (LMD-BT)</description>
    <arm_group_label>laser bladder tumor destruction</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ta low grade bladder tumor recurrences

          2. Up to a tumor size of 1,5 cm

          3. Up to 6 tumors

          4. Eligible patients for TUR-BT in GA

        Exclusion Criteria:

          1. Patients with porphyria

          2. Known hypersensitivity to Hexvix® or porfhyrins

          3. Use of concomitant anticoagulants as Marevan, Marcoumar, and Pradaxa

          4. Dementia

          5. Macroscopic hematuria

          6. Pregnant or breast feeding women

          7. Expected poor compliance estimated by the investigators

          8. Patients &lt; 18 years

          9. Patients who do not read or understand Danish
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregers G Hermann, DM Sc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Urology, Frederiksberg hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gregers G Hermann, DM Sc</last_name>
    <phone>+45 38163536</phone>
    <email>gregersgautierhermann@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Urological department, Frederiksberg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregers G Hermann, MD</last_name>
      <phone>+ 45 38163536</phone>
      <email>gregers.gautier.hermann@regionh.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2016</study_first_submitted>
  <study_first_submitted_qc>August 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2016</study_first_posted>
  <last_update_submitted>October 31, 2017</last_update_submitted>
  <last_update_submitted_qc>October 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Bispebjerg and Frederiksberg</investigator_affiliation>
    <investigator_full_name>Gregers Gautier Hermann</investigator_full_name>
    <investigator_title>Consultant Urologist</investigator_title>
  </responsible_party>
  <keyword>Laser</keyword>
  <keyword>Bladder cancer</keyword>
  <keyword>Treatment</keyword>
  <keyword>Outpatient</keyword>
  <keyword>TUR-BT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

